Jiangsu Bioperfectus Technologies Co (688399) Fair Value & Analysis
Healthcare · CN · Market cap 4.3B CNY
Fair value as of: Jul 12, 2026
From 4 valuation models · updated today
Fair value updated Jul 12, 2026 — revised from ¥157.13 to ¥11.12 (−92.9%) since Jun 24, 2026. Share price −30.6% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥32.29 – ¥84.90 · fair‑value band ¥10.06 – ¥12.19 · the ¥32.29 price screens above the ¥11.12 fair value. As of Jul 12, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Jiangsu Bioperfectus Technologies Co (688399) currently trades at ¥32.29, while our model-based Fair Value estimate is ¥11.12 — implying the stock looks roughly 65.6% overvalued today. We read business quality at 36/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Jiangsu Bioperfectus Technologies Co generated revenue of 326M CNY at a net margin of -10.1%. Revenue declined 14.2% year over year. It earns a return on equity of -1.1%. The balance sheet holds a net cash position of 576M CNY. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥10.06 (bear case) to ¥12.19 (bull case); at ¥32.29, the current price sits above that range. The share trades about 66% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside — at -66%, 688399 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.
About the company
Jiangsu Bioperfectus Technologies Co., Ltd., a molecular diagnostic company, engages in the research, development, production, and sale of in vitro diagnostic products in China. The company offers in vitro diagnostic reagents and supporting testing equipment, as well as in vitro testing services. It also provides HPV and cervical cancer testing services, respiratory infection detection solution, solutions for infectious diarrhea, and STI detection solution for reproductive tract infections. Jiangsu Bioperfectus Technologies Co., Ltd. was founded in 2010 and is headquartered in Taizhou, China.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jiangsu Bioperfectus Technologies Co reported revenue of ¥340M in FY2025 versus ¥2.8B in FY2021, a compound −41.2%/yr. Reported net income was −¥39.7M in FY2025.
Is 688399 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$582.92 | R$95.50 | -84% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
| Alnylam Pharmaceuticals, Inc ALNY | $303.64 | $110.31 | -64% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jiangsu Bioperfectus Technologies Co (688399) undervalued?
What is the fair value of 688399?
What is the quality score of 688399?
What is the revenue of Jiangsu Bioperfectus Technologies Co (688399)?
What is the net profit margin of 688399?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Jiangsu Bioperfectus Technologies Co analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.